Proteomic Screen IDs Potential Use for GlaxoSmithKline Inhibitor in Treating Leukemia
October 07, 2011
Proteomic Screen IDs Potential Use for GlaxoSmithKline Inhibitor in Treating Leukemia
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- GSK to Buy Cellzome for $99M as Pharma Interest in Chemical Proteomics Continues to Build
May 18, 2012 / ProteoMonitor - Cellzome Snags More Than $3.1M in Grants for EU-, UK-Sponsored Research Initiatives
December 9, 2011 / ProteoMonitor - CRC Study IDs Extensive Proteome Changes Between Healthy and Tumor Tissue but Few in Metastases
September 21, 2012 / ProteoMonitor - Cellzome Uses New, High-Throughput Kinobeads Platform to Develop Inhibitor for PI3K Isoform
May 4, 2012 / ProteoMonitor - Cellzome Wins $1.5M UK Grant for Work with Pfizer to Characterize Therapeutic Stem Cells
December 9, 2011 / ProteoMonitor